Envoy Medical Secures Four New Global Patents, Expanding Its Leadership Position in Fully Implantable Hearing Technology
Envoy Medical (NASDAQ: COCH) has secured four new global patents, strengthening its position in fully implantable hearing technology. The patents include three Australian patents and one U.S. patent, focusing on programming cochlear implant accessories, lead characterization, and integrated signal analysis functionality.
These patents enhance Envoy Medical's ability to develop and protect innovations for next-generation cochlear implant solutions that offer patients a discreet, 24/7 hearing experience without external components. CEO Brent Lucas emphasized that these patents represent a crucial step in strengthening their global intellectual property portfolio and advancing their mission to deliver transformative hearing solutions.
Envoy Medical (NASDAQ: COCH) ha ottenuto quattro nuovi brevetti internazionali, rafforzando la propria posizione nella tecnologia per impianti cocleari completamente impiantabili. I brevetti comprendono tre brevetti australiani e un brevetto statunitense, e riguardano la programmazione degli accessori per impianti cocleari, la caratterizzazione dei fili/elettrodi e funzionalità integrate di analisi del segnale.
Questi brevetti potenziano la capacità di Envoy Medical di sviluppare e tutelare innovazioni per soluzioni cocleari di nuova generazione che offrono ai pazienti un’esperienza uditiva discreta 24/7 senza componenti esterni. L’amministratore delegato Brent Lucas ha sottolineato che si tratta di un passo fondamentale per rafforzare il portafoglio di proprietà intellettuale globale e per avanzare nella missione di fornire soluzioni uditive trasformative.
Envoy Medical (NASDAQ: COCH) ha logrado cuatro nuevas patentes globales, reforzando su posición en tecnología auditiva totalmente implantable. Las patentes incluyen tres patentes australianas y una patente estadounidense, centradas en la programación de accesorios para implantes cocleares, la caracterización de electrodos y funcionalidades integradas de análisis de señal.
Estas patentes mejoran la capacidad de Envoy Medical para desarrollar y proteger innovaciones para soluciones cocleares de próxima generación que ofrecen a los pacientes una experiencia auditiva discreta las 24 horas del día sin componentes externos. El CEO Brent Lucas destacó que representan un paso clave para fortalecer su cartera global de propiedad intelectual y avanzar en su misión de ofrecer soluciones auditivas transformadoras.
Envoy Medical (NASDAQ: COCH)는 완전 이식형 청각 기술 분야에서 입지를 강화하는 네 건의 신규 글로벌 특허를 확보했습니다. 이 특허들은 호주 특허 세 건과 미국 특허 한 건으로, 인공와우 임플란트 액세서리의 프로그래밍, 리드(전극) 특성 분석 및 통합 신호 분석 기능을 다룹니다.
이 특허들은 Envoy Medical이 외부 부품 없이 환자에게 24시간 은밀한 청취 경험을 제공하는 차세대 인공와우 솔루션에 대한 혁신을 개발하고 보호하는 능력을 향상시킵니다. CEO Brent Lucas는 이 특허들이 글로벌 지식재산 포트폴리오를 강화하고 변혁적 청각 솔루션 제공이라는 사명을 진전시키는 중요한 단계라고 강조했습니다.
Envoy Medical (NASDAQ: COCH) a obtenu quatre nouveaux brevets mondiaux, renforçant sa position dans la technologie auditive entièrement implantable. Les brevets comprennent trois brevets australiens et un brevet américain, portant sur la programmation des accessoires d’implant cochléaire, la caractérisation des électrodes/sondes et des fonctionnalités intégrées d’analyse du signal.
Ces brevets renforcent la capacité d’Envoy Medical à développer et protéger des innovations pour des solutions cochléaires de nouvelle génération offrant aux patients une expérience auditive discrète 24h/24 sans composants externes. Le PDG Brent Lucas a souligné qu’il s’agit d’une étape clé pour consolider leur portefeuille mondial de propriété intellectuelle et faire progresser leur mission de fournir des solutions auditives transformatrices.
Envoy Medical (NASDAQ: COCH) hat vier neue globale Patente gesichert und damit seine Stellung in der vollständig implantierbaren Hörtechnologie gestärkt. Die Patente umfassen drei australische Patente und ein US-Patent und befassen sich mit der Programmierung von Cochlea-Implantat-Zubehör, der Charakterisierung von Elektroden/Leads sowie integrierten Signalanalysefunktionen.
Diese Patente verbessern Envoy Medicals Fähigkeit, Innovationen für Cochlea-Implantat-Lösungen der nächsten Generation zu entwickeln und zu schützen, die Patienten ein diskretes 24/7-Hörerlebnis ohne externe Komponenten bieten. CEO Brent Lucas betonte, dass es sich um einen entscheidenden Schritt zur Stärkung ihres globalen geistigen Eigentumsportfolios und zur Weiterverfolgung ihrer Mission handelt, transformative Hörlösungen bereitzustellen.
- Secured four new global patents strengthening intellectual property portfolio
- Patents cover critical technologies for cochlear implant programming and maintenance
- Technology advances aim to eliminate burdens of external wearable hardware
- Expands company's competitive position in fully implanted hearing solutions
- None.
Insights
Envoy Medical strengthens IP portfolio with four new patents protecting its fully implantable cochlear implant technology, enhancing competitive position.
Envoy Medical (NASDAQ: COCH) has secured four strategic patents that significantly bolster its intellectual property position in the fully implantable hearing technology space. The newly issued patents - one U.S. and three Australian - cover critical technical innovations for the company's next-generation cochlear implant solutions.
The U.S. patent addresses programming and connectivity challenges by establishing protected methods for communicating with, charging, and pairing multiple cochlear implant accessory devices. This solves a key user experience challenge in implantable hearing technology.
The Australian patents cover three distinct technological innovations: lead characterization between cochlear implant components, accessory device pairing systems, and integrated signal analysis functionality. Collectively, these patents protect methods that could substantially improve device reliability, usability, and diagnostic capabilities.
The strategic significance of these patents extends beyond mere legal protection. By securing exclusive rights to these technological approaches, Envoy has established defensive barriers against competitors while protecting its development pathway toward fully implantable solutions that eliminate external components - a key differentiator in the hearing technology market.
For investors, this patent expansion represents tangible progress in Envoy's R&D pipeline and strengthens its competitive moat in the cochlear implant market. The timing of these patents suggests Envoy is methodically building protection around a comprehensive technology platform rather than pursuing isolated innovations. This systematic approach to IP development typically indicates a well-defined product roadmap and robust R&D strategy.
Patents strengthen Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.
White Bear Lake, Minnesota--(Newsfile Corp. - September 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of four new global patents. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience without the limitation of externally worn components.
The following patents are being issued to Envoy Medical:
- U.S. Patent No. 12,418,758 on September 16, 2025. The title is Programming of Cochlear Implant Accessories. This patent will relate to systems and methods for easily communicating with, charging, and pairing multiple cochlear implant accessory devices.
- Australian Patent No. 2020224666, on August 7, 2025. The title is Implantable Cochlear System with Integrated Components and Lead Characterization. This patent relates to characterizing conductors between components of a cochlear implant system by grounding one conductor and applying a test signal to a different conductor.
- Australian Patent No. 2021334336 on July 31, 2025. The title is Programming of Cochlear Implant Accessories. This patent relates to systems and methods for easily communicating with and pairing accessory devices to a cochlear implant system.
- Australian Patent No. 2022227536 on July 24, 2025. The title is Cochlear Implant System with Integrated Signal Analysis Functionality. This patent relates to using an external device to designate a signal within a fully implantable cochlear implant system for analysis and to receive a representative signal from the cochlear implant system.
"These four new patents represent yet another important step in strengthening our global intellectual property portfolio and reinforcing our position at the forefront of fully implanted hearing solutions," said Brent Lucas, Chief Executive Officer of Envoy Medical. "The granted patents cover critical technologies to support improvements in how our cochlear implant device is programmed and maintained, aligning with our mission to deliver discreet, intuitive, and life-changing hearing experiences. As we continue to develop and protect innovations that eliminate the burdens of external wearable hardware, we are proud to be another step closer to bringing transformative hearing solutions to more patients around the world."
For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
SOURCE: Envoy Medical, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265566
FAQ
What new patents did Envoy Medical (NASDAQ: COCH) receive in 2025?
How will these new patents benefit Envoy Medical's cochlear implant technology?
What is unique about Envoy Medical's cochlear implant approach?
When will the U.S. Patent No. 12,418,758 be issued to Envoy Medical?
Who is the CEO of Envoy Medical (NASDAQ: COCH)?
